<--- Back to Details
First PageDocument Content
Stroke / Anticoagulants / Hematology / Cardiac dysrhythmia / Medical emergencies / Apixaban / Rivaroxaban / Dabigatran / Warfarin / Chemistry / Organic chemistry / Medicine
Date: 2014-10-01 21:56:23
Stroke
Anticoagulants
Hematology
Cardiac dysrhythmia
Medical emergencies
Apixaban
Rivaroxaban
Dabigatran
Warfarin
Chemistry
Organic chemistry
Medicine

Microsoft WordRivaroxaban NOAC review Bayer PSD March 2013 FINAL.doc

Add to Reading List

Source URL: www.pbs.gov.au

Download Document from Source Website

File Size: 156,96 KB

Share Document on Facebook

Similar Documents

*** Drug Safety Alert *** Xarelto (Rivaroxaban) Tablets FDA MedWatch - August 2013 Safety Labeling Changes with revisions to Prescribing Information [PostedThe MedWatch August 2013 Safety Labeling Changes po

DocID: 1t7rk - View Document

Microsoft Word - frommtg draft uspi xarelto rivaroxaban.doc

DocID: 1sPZ1 - View Document

MEDICATION GUIDE XARELTO® (zah-REL-toe) (rivaroxaban) tablets Read this Medication Guide before you start taking XARELTO and each time you get a refill. There may be new information. This Medication Guide does not take

DocID: 1scq8 - View Document

Anticoagulants / RTT / Clinical pharmacology / Lactams / Medical terminology / Warfarin / Compliance / Rivaroxaban / Stroke / Dabigatran / Atrial fibrillation / Edoxaban

Atrial Fibrillation (AFib) Treatment Adherence Following your treatment plan will reduce your risk of AFib-related stroke. it can enter the bloodstream and cause a stroke. A stroke means

DocID: 1pjDF - View Document

Food and Drug Administration / Clinical research / Thiophenes / Healthcare quality / Medical terminology / Adverse Event Reporting System / Duloxetine / Pharmacovigilance / Rivaroxaban / Adverse effect / Adverse event / MedWatch

QuarterWatch Monitoring FDA MedWatch Reports Why Reports of Serious Adverse Drug Events Continue to Grow October 3, 2012 Data from 2012 Quarter 1

DocID: 1p1ui - View Document